A hot cell licence at Bruce Power shortens the lutetium-177 chain by an unpublished amount

The release calls Target Carrier Removal an important step in producing lutetium-177 and leaves it at that, with no account of what the step does to the irradiated material ^[2]. The benefit list is more informative. Bruce Power puts reduced transportation requirements alongside worker safety and lower emissions ^[4], and a company does not claim a shipping saving from a new building unless the work that building houses was previously being done somewhere a shipment had to reach. That reading is ours rather than Bruce Power's, which describes the change only as bringing the capability to site ^[16].

What is absent is the figure that would tell you whether any of this tightens delivery: no lead time before or after, no count of handoffs eliminated, no throughput for the cell, no build cost, and no date for the Commission's decision ^[15]. The company's stated gains are efficiency and a strengthened Ontario supply chain, in the words of chief operating officer James Scongack ^[5]. Efficiency stated without a denominator is a position, not a measurement.

The one hard mechanism on offer is the cell itself, which lets qualified operators handle irradiated material remotely and keeps exposure down ^[7]. That is a real change in how the work is done, and it is also the reason the step needed a licence rather than a procedure change.

The pace here is worth noticing. Cobalt-60 has come out of Bruce since 1986, and isotopes from the site sterilise roughly 30 per cent of the world's single-use medical devices ^[8]. Medical-grade cobalt-60 for cancer treatment followed in 2021, 35 years later, and the first lutetium-177 from a commercial power reactor a year after that, in 2022 ^[9][10][14]. Each move waited on approvals rather than on demand, and the hot cell, finished earlier this year with Kinectrics, Bird Construction and internal engineering and licensing teams, has been standing built and unlicensed since ^[6].

One more thing about the announcement's audience: the second voice in it belongs to Lisa Thompson, MPP for Huron-Bruce and Minister of Rural Affairs, who frames the approval as an investment in the region's economic future ^[13]. The isotope story and the rural industrial story are being told in the same paragraph.

For anyone buying lutetium-177 for prostate-cancer therapy or the other targeted treatments that use it ^[3], the question is how many days come out of the order-to-dose interval. Nobody has published that number, and until somebody does, this is a licensed room with a plausible claim attached.